ENTITY
Zai Lab Ltd

Zai Lab Ltd (ZLAB US)

131
Analysis
Health CareChina
Zai Lab Limited operates as a bio-pharmaceutical company. The Company researches and develops therapeutic technology for antibody-based oncology, autoimmune, and infectious diseases treatments. Zai Lab also manufactures drugs in the form of capsules, injections, and liquids. Zai Lab serves patients worldwide.
more
Refresh
bearishS&P 500 INDEX
19 Mar 2020 19:56

S&P 500 Technical Appraisal and Support Levels

S&P 500 Potential Support Levels. Current logical support levels we are monitoring include the December 2018 low of 2,346 and prior resistance...

Logo
409 Views
Share
26 Jan 2020 11:42

ECM Weekly (26 Jan 2020) - Central Retail Corp, Smoore, Mindspace Biz Parks REIT, Elite Comm REIT

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Happy...

Share
bullishZai Lab Ltd
22 Jan 2020 14:32

Zai Lab Placement: Positive Development Bodes Well for the Deal

Zai Lab announced a USD 300 million placement after market close. This is the third deal since its IPO in 2017. In this insight, we will discuss...

Logo
466 Views
Share
bullishZai Lab Ltd
22 Jan 2020 12:00

Zai Lab Offering: Remains an Attractive Opportunity

Zai Lab Ltd (ZLAB US) unveiled plans to raise around $313 million (based on the closing price of $52.14 per ADS) through a primary offering of 5.5...

Logo
430 Views
Share
bullishZai Lab Ltd
02 May 2019 22:19

Zai Lab Offering: Attractive Due to Strong Track Record

Zai Lab Ltd (ZLAB US) unveiled plans to raise around $125 million (based on the closing price of $26.65 per ADS) through a public offering of 5.0...

Logo
506 Views
Share
x